文献速递心律失常冠心病血脂与心血管预防

心房颤动临床表型与治疗模式及结局的关联:多中心注册研究

Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study.
PubMed 文献 · JAMA Cardiol · 2018-01-01

该研究基于ORBIT-AF注册的9749例房颤患者,用60项基线特征聚类分析识别出4种临床表型,并评估其与治疗及结局的关联。与低合并症表型相比,其他3种表型的主要不良心脑血管事件风险显著更高,且部分表型大出血风险也升高。

要点

  • 房颤可聚类为4种临床表型,传统房颤亚型与左房大小未驱动聚类形成。
  • 行为合并症、器械植入及动脉粥样硬化合并症表型的主要不良事件风险均高于低合并症表型。
  • 行为合并症与器械植入表型的大出血风险也显著高于低合并症表型。

核心结论

  • 聚类分析识别出4种与临床结局有不同关联的房颤表型,凸显房颤异质性及合并症与基质的重要性。

研究设计与样本

  • 观察性队列的聚类分析,纳入ORBIT-AF注册中174个美国中心的9749例房颤患者,数据分析于2017年1月至10月完成。

主要发现

  • 9749例患者中4150例(42.6%)为女性,8719例(89.4%)为白人,477例(4.9%)为非裔美国人。
  • 基于60项基线临床特征聚类出4种表型:低合并症表型(n=4673)、年轻和/或行为合并症表型(n=963)、类似快慢综合征且因窦房结功能障碍植入器械表型(n=1651)、动脉粥样硬化合并症表型(n=2462)。
  • 与低合并症表型相比,主要不良心脑血管事件调整后风险:行为合并症表型HR 1.49(95%CI 1.10-2.00),器械植入表型HR 1.39(95%CI 1.15-1.68),动脉粥样硬化合并症表型HR 1.59(95%CI 1.31-1.92)。
  • 与低合并症表型相比,大出血调整后风险:行为合并症表型HR 1.35(95%CI 1.05-1.73),器械植入表型HR 1.24(95%CI 1.05-1.47),动脉粥样硬化合并症表型HR 1.13(95%CI 0.96-1.33)。
  • 在ORBIT AF II注册的外部验证中识别出相同的聚类。

关键数值与推荐

  • 主要结局为国际血栓与止血学会标准定义的主要不良心脑血管事件与大出血的复合终点。

临床怎么用

  • 临床可依据合并症与基质特征对房颤患者进行表型分层,以识别主要不良事件和大出血风险更高的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Atrial fibrillation (AF) is usually classified on the basis of the disease subtype. However, this characterization does not capture the full heterogeneity of AF, and a data-driven cluster analysis reveals different possible classifications of patients. OBJECTIVE: To characterize patients with AF based on a cluster analysis and to evaluate the association between these phenotypes, treatment, and clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: This cluster analysis used data from an observational cohort that included 9749 patients with AF who had been admitted to 174 US sites participating in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Data analysis was completed from January 2017 to October 2017. EXPOSURE: Patients with diagnosed AF who were included in the registry. MAIN OUTCOMES AND MEASURES: Composite of major adverse cardiovascular or neurological events and major bleeding, as defined by the International Society of Thrombosis and Hemostasis criteria. RESULTS: Of 9749 total patients, 4150 (42.6%) were female; 8719 (89.4%) were white and 477 (4.9%) were African American. A cluster analysis was performed using 60 baseline clinical characteristics, and it classified patients with AF into 4 statistically driven clusters: (1) those with considerably lower rates of risk factors and comorbidities than all other clusters (n = 4673); (2) those with AF at younger ages and/or with comorbid behavioral disorders (n = 963); (3) those with AF who had similarities to patients with tachycardia-brachycardia and had device implantation owing to sinus node dysfunction (n = 1651); and (4) those with AF and prior coronary artery disease, myocardial infarction, and/or atherosclerotic comorbidities (n = 2462). Conventional classifications, such as AF subtype and left atrial size, did not drive cluster formation. Compared with the low comorbidity AF cluster, adjusted risks of major adverse cardiovascular or neurological events were significantly higher in the other 3 clusters (behavioral comorbidity cluster: hazard ratio [HR], 1.49; 95% CI, 1.10-2.00; device implantation cluster: HR, 1.39; 95% CI, 1.15-1.68; and atherosclerotic comorbidity cluster: HR, 1.59; 95% CI, 1.31-1.92). For major bleeding, adjusted risks were higher in the behavioral disorder comorbidity cluster (HR, 1.35; 95% CI, 1.05-1.73), those with device implantation (HR, 1.24; 95% CI, 1.05-1.47), and those with atherosclerotic comorbidities (HR, 1.13; 95% CI, 0.96-1.33) compared with the low comorbidity cluster. The same clusters were identified in an external validation in the ORBIT AF II registry. CONCLUSIONS AND RELEVANCE: Cluster analysis identified 4 clinically relevant phenotypes of AF that each have distinct associations with clinical outcomes, underscoring the heterogeneity of AF and importance of comorbidities and substrates.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Inohara T, Shrader P, Pieper K, et al. Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study. JAMA Cardiol. 2018. PMID: 29128866. doi:10.1001/jamacardio.2017.4665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。